Updates in the management of polycythemia vera and essential thrombocythemia

by Prithviraj Bose, Srdan Verstovsek
Published 2019-08-01

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives

by Prithviraj Bose, Srdan Verstovsek
Published 2020-08-01

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

by Ostojic A, Vrhovac R, Verstovsek S
Published 2012-03-01

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

by Vaddi K, Verstovsek S, Kiladjian JJ
Published 2016-05-01

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms

by Prithviraj Bose, Lucia Masarova, Srdan Verstovsek
Published 2020-10-01

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

by Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S
Published 2014-01-01

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

by Randhawa Jasleen, Ostojic Alen, Vrhovac Radovan, Atallah Ehab, Verstovsek Srdan
Published 2012-08-01

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

by Singer J, Al-Fayoumi S, Ma H, Komrokji R, Mesa R, Verstovsek S
Published 2016-08-01

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

by Srdan Verstovsek, Olatoyosi Odenike, Jack W. Singer, Tanya Granston, Suliman Al-Fayoumi, H. Joachim Deeg
Published 2016-12-01

Primary bone lymphoma of the ilium successfully treated without radiation

by Charles B. Nguyen, Monica Li, Gordana Verstovsek, Urmi Sen, Christi Swierenga, Quillan Huang, Gustavo Rivero, Sarvari V. Yellapragada
Published 2020-12-01

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

by Hans Michael Kvasnicka, Jürgen Thiele, Carlos E. Bueso-Ramos, William Sun, Jorge Cortes, Hagop M. Kantarjian, Srdan Verstovsek
Published 2018-03-01

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.

by Taghi Manshouri, Srdan Verstovsek, David M Harris, Ivo Veletic, Xiaorui Zhang, Sean M Post, Carlos E Bueso-Ramos, Zeev Estrov
Published 2019-01-01

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

by Iman Abou Dalle, Hagop Kantarjian, Jan Burger, Zeev Estrov, Maro Ohanian, Srdan Verstovsek, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia‐Manero, Elias Jabbour, Jorge Cortes
Published 2019-11-01

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

by Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA
Published 2013-12-01

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

by Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi, Francesco Passamonti
Published 2018-09-01

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

by Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Srdan Verstovsek
Published 2017-11-01

Extramedullary Acute Myeloid Leukemia (AML): Leukemic Pleural Effusion, Case Report and Review of the Literature

by Naveen ePemmaraju, Elaine eChang, Naval eDaver, Keyur ePatel, Jeffrey eJorgensen, Bradley eSabloff, Srdan eVerstovsek, Gautam eBorthakur
Published 2014-06-01

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

by Srdan Verstovsek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N. Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna, Vikas Gupta
Published 2017-09-01

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Plac...

by Ruben A. Mesa, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Pranav Abraham, Jennifer Lord-Bessen, Derek Tang, Shien Guo, Xiaomei Ye, Claire N. Harrison
Published 2021-05-01

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes...

by Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Derek Tang, Pranav Abraham, Jennifer Lord-Bessen, Shelonitda Rose, Shien Guo, Weiqin Liao, Ruben A. Mesa
Published 2021-05-01